letrozole has been researched along with Musculoskeletal Diseases in 8 studies
Musculoskeletal Diseases: Diseases of the muscles and their associated ligaments and other connective tissue and of the bones and cartilage viewed collectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined 12 consecutive non-metastatic breast cancer patients who reported severe musculoskeletal pain under a third generation AI; 11 were on letrozole and 1 on exemestane." | 7.74 | Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. ( Amant, F; Berteloot, P; Christiaens, MR; De Smet, L; Leunen, K; Morales, L; Neven, P; Pans, S; Paridaens, R; Smeets, A; Timmerman, D; Van den Bogaert, W; Van Limbergen, E; Vergote, I; Verhaeghe, J; Weltens, C; Westhovens, R; Wildiers, H, 2007) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 6.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - positive breast cancer in postmenopausal women." | 4.84 | The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. ( Fabian, CJ, 2007) |
| "We conducted a prospective study including postmenopausal early breast cancer patients receiving either an aromatase inhibitor (AI) or tamoxifen." | 3.77 | Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. ( Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H, 2011) |
| "We examined 12 consecutive non-metastatic breast cancer patients who reported severe musculoskeletal pain under a third generation AI; 11 were on letrozole and 1 on exemestane." | 3.74 | Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. ( Amant, F; Berteloot, P; Christiaens, MR; De Smet, L; Leunen, K; Morales, L; Neven, P; Pans, S; Paridaens, R; Smeets, A; Timmerman, D; Van den Bogaert, W; Van Limbergen, E; Vergote, I; Verhaeghe, J; Weltens, C; Westhovens, R; Wildiers, H, 2007) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 2.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, O | 1 |
| Kisaoglu, H | 1 |
| Kalyoncu, M | 1 |
| Shapiro, AC | 1 |
| Adlis, SA | 1 |
| Robien, K | 1 |
| Kirstein, MN | 1 |
| Liang, S | 1 |
| Richter, SA | 1 |
| Lerner, RE | 1 |
| Liedke, PE | 1 |
| Tu, D | 1 |
| Shepherd, L | 1 |
| Chavarri-Guerra, Y | 1 |
| Pritchard, KI | 1 |
| Stearns, V | 1 |
| Goss, PE | 1 |
| Briot, K | 1 |
| Tubiana-Hulin, M | 1 |
| Bastit, L | 1 |
| Kloos, I | 1 |
| Roux, C | 1 |
| Lintermans, A | 1 |
| Van Calster, B | 1 |
| Van Hoydonck, M | 1 |
| Pans, S | 2 |
| Verhaeghe, J | 2 |
| Westhovens, R | 2 |
| Henry, NL | 1 |
| Wildiers, H | 2 |
| Paridaens, R | 3 |
| Dieudonné, AS | 1 |
| Leunen, K | 2 |
| Morales, L | 3 |
| Verschueren, K | 1 |
| Timmerman, D | 3 |
| De Smet, L | 2 |
| Vergote, I | 3 |
| Christiaens, MR | 3 |
| Neven, P | 3 |
| Van Limbergen, E | 2 |
| Carbonez, A | 1 |
| Van Huffel, S | 1 |
| Ameye, L | 1 |
| Amant, F | 1 |
| Berteloot, P | 1 |
| Smeets, A | 1 |
| Weltens, C | 1 |
| Van den Bogaert, W | 1 |
| Fabian, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors[NCT01509079] | Phase 2 | 116 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
adherence measured with pill counts for the vitamin D at predesignated study timepoints: baseline (after run-in), 3 months and 6 months (NCT01509079)
Timeframe: average for all study ppts for: screening to baseline; baseline to 3 months; 3 month to 6 months
| Intervention | % of adherence for each treatment arm (Number) |
|---|---|
| Vitamin D3 4000 IU | 95 |
| Vitamin D3 600 IU | 95 |
(NCT01509079)
Timeframe: baseline to 6 months
| Intervention | pounds (Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.8 |
| Vitamin D3 600 IU | 1.0 |
The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | -0.2 |
| Vitamin D3 600 IU | -0.5 |
PROMIS measures physical functioning on the short form and higher scores reflect better physical functioning with 10 questions on daily activities of life on a Likert scale ranging from 5 (no problem performing activity) to 1 (cannot do activity). Range on this measure is from 50 (best)-10 (worst). (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | 0.6 |
| Vitamin D3 600 IU | 1.7 |
GLM Mean and standard deviation of Whole Body Bone Mineral Density (grams/cm2) of Trial Participants by Treatment Arm after controlling for bisphosphonate use (NCT01509079)
Timeframe: From Baseline and 6 months of D3 supplementation
| Intervention | gm/cm2 (Geometric Least Squares Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.1 |
| Vitamin D3 600 IU | 1.12 |
Difference in steady state concentrations in plasma from baseline to 6 months (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | mg/L (Mean) | |
|---|---|---|
| anastrozole | letrozole | |
| Vitamin D3 4000 IU | -1.31 | 2.16 |
| Vitamin D3 600 IU | 2.4 | -0.83 |
(NCT01509079)
Timeframe: baseline and 6 months
| Intervention | pg/ml (Geometric Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Vitamin D3 4000 IU | 2.83 | 2.94 |
| Vitamin D3 600 IU | 2.77 | 3.0 |
1 review available for letrozole and Musculoskeletal Diseases
| Article | Year |
|---|---|
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemot | 2007 |
4 trials available for letrozole and Musculoskeletal Diseases
| Article | Year |
|---|---|
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone De | 2016 |
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Breast Neoplasms; Chemotherapy, Adju | 2016 |
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2010 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
3 other studies available for letrozole and Musculoskeletal Diseases
| Article | Year |
|---|---|
Letrozole-induced inflammatory arthritis and tendinopathy in pediatric rheumatology setting.
Topics: Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Child; Female; Humans; Letrozole; Mus | 2023 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplas | 2011 |
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Female; Humans | 2007 |